Apollomics Inc. (APLM) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Apr 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the APLM SEC filings page.
Apollomics Inc. (APLM) reported $8.5M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has begun reporting sales, but its first revenue base still falls short of covering operating costs and cash outflows.
In FY2025, the net loss was$10.9M against operating cash flow of-$10.4M , so accounting performance and cash consumption were closely aligned rather than separated by a large non-cash adjustment. Free cash flow of-$10.4M was nearly identical to operating cash flow, indicating that reported investment spending was not the main drain.
FY2025 was the first period with reported revenue, at
FY2024's complete balance sheet showed a 1.4x current ratio and
Financial Health Signals
Apollomics Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Apollomics Inc. reported a net loss of $10.9M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q3 2025.
Cash & Balance Sheet
Apollomics Inc. held $9.8M in cash against $733K in long-term debt as of Q3 2025.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
None of these metrics is reported for Q3 2025.
Capital Allocation
None of these metrics is reported for Q3 2025.
APLM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
APLM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-K | Q1'2510-Q | Q3'2410-K | Q1'2410-Q | Q3'2310-K | Q3'2210-K |
|---|---|---|---|---|---|---|
| Total Assets | $13.1M-76.4% | $34.6M-51.6% | $55.4M-27.6% | $71.4M | $76.5M-38.0% | $123.4M |
| Current Assets | $10.3M-74.3% | $28.4M-48.7% | $39.9M-28.4% | $55.4M | $55.8M-43.9% | $99.4M |
| Cash & Equivalents | $9.8M-69.5% | $25.9M+2.5% | $32.1M-1.9% | $25.3M | $32.7M-30.1% | $46.7M |
| Total Liabilities | $8.2M-41.8% | $13.8M-12.2% | $14.2M-97.3% | $15.7M | $524.6M+56.0% | $336.3M |
| Current Liabilities | $7.4M-45.4% | $12.6M-10.5% | $13.6M+9.7% | $14.1M | $12.4M-8.8% | $13.6M |
| Non-Current Liabilities | $835K+39.9% | $1.1M-27.7% | $597K-99.9% | $1.5M | $512.2M+58.7% | $322.7M |
| Long-Term Debt | $733K+174.5% | $951K+223.5% | $267K-29.2% | $294K | $377K-28.6% | $528K |
| Total Equity | $4.9M-88.2% | $20.8M-62.6% | $41.2M+109.2% | $55.7M | -$448.1M-110.5% | -$212.9M |
| Retained Earnings | -$700.8M-8.3% | -$682.2M-9.1% | -$647.0M-36.3% | -$625.1M | -$474.6M-101.6% | -$235.4M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill.
APLM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
APLM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Apollomics Inc. APLM | FY2025 | $8.5M | -$10.9M | N/A | $63.5M | — |
| NextCure, Inc. NXTC | FY2025 | N/A | -$55.8M | N/A | $30.1M | — |
| Briacell Therapeutics Corp. BCTX | FY2025 | N/A | -$26.3M | N/A | $32.1M | — |
| Cyclacel Pharmaceuticals, Inc CYCC | FY2025 | $747K | $3.0M | N/A | $15.2M | — |
| Adaptimmune Therapeutics plc American ADAP | FY2024 | $178.0M | -$70.8M | -39.8% | $14.6M | 46/100 |
| Minerva Neurosciences, Inc NERV | FY2025 | N/A | -$293.4M | N/A | $112.2M | — |
Where Apollomics Inc. Ranks
Frequently Asked Questions
What is Apollomics Inc.'s annual revenue?
Apollomics Inc. (APLM) reported $8.5M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Apollomics Inc. profitable?
No, Apollomics Inc. (APLM) reported a net income of -$10.9M in fiscal year 2025.
What is Apollomics Inc.'s free cash flow?
Apollomics Inc. (APLM) recorded an outflow of $10.4M in free cash flow during fiscal year 2025. This represents a 63.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Apollomics Inc.'s operating cash flow?
Apollomics Inc. (APLM) recorded an outflow of $10.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Apollomics Inc.'s capital expenditures?
Apollomics Inc. (APLM) invested $24K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Apollomics Inc.'s P/E ratio?
Apollomics Inc. (APLM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $63.5M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Apollomics Inc.'s price-to-sales ratio?
Apollomics Inc. (APLM) trades at 7.5x sales, its market capitalization divided by revenue of $8.5M revenue, FY2025. The market capitalization is $63.5M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Are Apollomics Inc.'s earnings high quality?
Apollomics Inc. (APLM) reported a net loss of $10.9M while operations used $10.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.